Madrigal Pharmaceuticals Inc

MDGL

Equity

ISIN null / Valor 33395434

NASDAQ (2026-06-04)

USD 492.83+0.96%

Madrigal Pharmaceuticals Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Madrigal Pharmaceuticals Inc. is a biopharmaceutical entity focused on the development of innovative treatments for nonalcoholic steatohepatitis (NASH), a condition also referred to as metabolic dysfunction associated steatohepatitis (MASH). The company has made significant strides in this therapeutic area, with its first therapy receiving accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of adults exhibiting moderate to advanced liver fibrosis, which corresponds to stages F2 to F3 fibrosis, a critical subset of the NASH patient population. Furthermore, Madrigal is advancing its research and development efforts by conducting a Phase 3 trial aimed at evaluating the efficacy of its therapy in treating NASH with compensated cirrhosis, demonstrating its commitment to addressing the unmet medical needs within this patient community.

Summarized from source with an LLMView SourceSector: Healthcare

Rezdiffra net sales

Product revenue: Q4 2025 $321.1M (vs. $103.3M Q4 2024); FY 2025 $958.4M (vs. $180.1M FY 2024). Company reports >36,250 patients on Rezdiffra as of year-end 2025 and launched Rezdiffra in Germany after EC conditional approval.

Profitability / Net loss

Loss from operations: Q4 2025 $59.6M; FY 2025 $300.1M. Net loss: Q4 2025 $58.6M; FY 2025 $288.3M. Basic and diluted EPS: Q4 $(2.57); FY $(12.85).

Operating expense drivers

Total operating expenses: Q4 $380.7M (vs. $170.3M prior year); FY $1,258.5M (vs. $678.0M prior year). R&D: Q4 $116.3M, FY $388.5M (up due to BD upfronts); SG&A: Q4 $240.0M, FY $813.8M (increased commercial activity and headcount).

Cost of sales and margins

Cost of sales: Q4 $24.4M, FY $56.1M (versus $3.4M and $6.2M in prior-year periods), reflecting scale-up of product sales; gross margin expansion implied by revenue growth but offset by elevated operating costs.

Cash, balance sheet and receivables

Cash, cash equivalents, restricted cash and marketable securities: $988.6M as of Dec. 31, 2025 (up from $931.3M). Trade receivables: $134.5M. Total assets: $1,259.6M; current liabilities $310.3M; long-term liabilities $346.6M; stockholders’ equity $602.7M.

Financing and interest

Entered a senior secured credit facility (up to $500M) with a $350M initial term loan funded in July 2025 (partly used to repay prior facility). Interest expense rose to $22.3M for FY 2025 (from $14.7M) while interest income fell to $37.4M (from $46.7M).

Commercial & pipeline context

Beyond sales, Madrigal highlighted strategic wins that affect future financials: Orange Book-listed patent (protection into 2045), launch in the EU (Germany), licensing deals (siRNA programs, oral GLP‑1 MGL-2086, ervogastat) and an expanded >10-program MASH pipeline—all of which support continued R&D and commercial investment.

Summarized from source with an LLMView Source

Key figures

76.4%1Y

89.6%3Y

388%5Y

Performance

44.6%1Y

55.8%3Y

82.2%5Y

Volatility